119 related articles for article (PubMed ID: 15163174)
1. Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma.
Ribas C; Colleoni G; Almeida M; Duch CR; Ohashi C; Segreto R; Silva MR
Acta Oncol; 2004; 43(2):215-6. PubMed ID: 15163174
[No Abstract] [Full Text] [Related]
2. Low-dose of thalidomide in the treatment of refractory myeloma.
Pini M; Baraldi A; Pietrasanta D; Allione B; Depaoli L; Salvi F; Levis A
Haematologica; 2000 Oct; 85(10):1111-2. PubMed ID: 11025615
[No Abstract] [Full Text] [Related]
3. Unstable plasma thalidomide concentration in patients with refractory multiple myeloma.
Kodama T; Horiuchi R; Tsukamoto N; Nojima Y; Murakami H
Lab Hematol; 2004; 10(3):132-6. PubMed ID: 15479647
[TBL] [Abstract][Full Text] [Related]
4. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
[TBL] [Abstract][Full Text] [Related]
5. Response to thalidomide in multiple myeloma: impact of angiogenic factors.
Rosiñol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Bladé J; Montserrat E
Cytokine; 2004 May; 26(4):145-8. PubMed ID: 15149630
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide for the treatment of leptomeningeal multiple myeloma.
Yutaka H; Mariko Y; Shinichiro O; Kunihiko M; Yusuke T; Yasuo I
Eur J Haematol; 2006 Apr; 76(4):358-9. PubMed ID: 16519710
[No Abstract] [Full Text] [Related]
7. Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients.
Corso A; Lorenzi A; Zappasodi P; Invernizzi R; Vanelli L; Lazzarino M
Haematologica; 2003 Aug; 88(8):958-60. PubMed ID: 12935985
[No Abstract] [Full Text] [Related]
8. Thalidomide in multiple myeloma.
Kishi Y; Oki Y; Machida U
N Engl J Med; 2000 Mar; 342(13):975; author reply 975-6. PubMed ID: 10744492
[No Abstract] [Full Text] [Related]
9. Extramedullary multiple myeloma escapes the effect of thalidomide.
Rosiñol L; Cibeira MT; Bladé J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E
Haematologica; 2004 Jul; 89(7):832-6. PubMed ID: 15257935
[TBL] [Abstract][Full Text] [Related]
10. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
Prince HM; Mileshkin L; Roberts A; Ganju V; Underhill C; Catalano J; Bell R; Seymour JF; Westerman D; Simmons PJ; Lillie K; Milner AD; Iulio JD; Zeldis JB; Ramsay R
Clin Cancer Res; 2005 Aug; 11(15):5504-14. PubMed ID: 16061867
[TBL] [Abstract][Full Text] [Related]
11. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
[TBL] [Abstract][Full Text] [Related]
12. Encephalopathy in a patient after long-term treatment with thalidomide.
Sohlbach K; Heinze S; Shiratori K; Sure U; Pagenstecher A; Neubauer A
J Clin Oncol; 2006 Oct; 24(30):4942-4. PubMed ID: 17050881
[No Abstract] [Full Text] [Related]
13. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Hoiczyk M; Flasshove M; Hense J; Bojko P; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2005 Jan; 74(1):40-6. PubMed ID: 15613105
[TBL] [Abstract][Full Text] [Related]
14. [Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone].
Miyazawa Y; Irisawa H; Uchiumi H; Saitoh T; Handa H; Matsushima T; Tsukamoto N; Karasawa M; Murakami H; Nojima Y
Rinsho Ketsueki; 2006 Jul; 47(7):656-60. PubMed ID: 16910577
[TBL] [Abstract][Full Text] [Related]
15. Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma.
Murakami H; Handa H; Abe M; Iida S; Ishii A; Ishikawa T; Ishida T; Oota M; Ozaki S; Kosaka M; Sakai A; Sawamura M; Shimazaki C; Shimizu K; Takagi T; Hata H; Fukuhara T; Fujii H; Miyata A; Wakayama T; Takatsuki K
Eur J Haematol; 2007 Sep; 79(3):234-9. PubMed ID: 17655699
[TBL] [Abstract][Full Text] [Related]
16. [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].
Wasser K; Moehler T; Neben K; Nosas S; Heiss J; Goldschmidt H; Hillengass J; Düber C; Kauczor HU; Delorme S
Rofo; 2004 Sep; 176(9):1285-95. PubMed ID: 15346264
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of extramedullary plasmacytoma of the cavernous sinus using a combination of intermediate dose of thalidomide and dexamethasone.
Katodritou E; Speletas M; Pouli A; Tsitouridis J; Zervas K; Terpos E
Acta Haematol; 2007; 117(1):20-3. PubMed ID: 17106187
[No Abstract] [Full Text] [Related]
18. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
Cibeira MT; Rosiñol L; Ramiro L; Esteve J; Torrebadell M; Bladé J
Eur J Haematol; 2006 Dec; 77(6):486-92. PubMed ID: 16978238
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas.
Bladé J; Perales M; Rosiñol L; Tuset M; Montoto S; Esteve J; Cobo F; Villela L; Rafel M; Nomdedeu B; Montserrat E
Br J Haematol; 2001 May; 113(2):422-4. PubMed ID: 11380408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
